Clinigen enjoys a revenue surge
BURTON-on-Trent pharmaceuticals firm Clinigen Group has seen its half year revenues increase by 17% to £72.6m.
Announcing its results for the six months to December 31, the firm also revealed gross profit had increased by 11% to £22m (H1FY14: £19.9m).
Its underlying divisions all performed well. CTS saw 28% revenue growth and attracted 14 new customers, while GAP saw a 51% increase in units shipped and announced that seven new programmes will start in 2015 including its first programme for AstraZeneca for their product CAZ-AVI.
And SP saw sales and profit growth driven by new products and underlying volume growth in Foscavir.
Peter George, Clinigen’s chief executive officer, said: “After another strong first half, with all three divisions making good profit contributions, we are in a great position to continue our ambitious pursuit to become the world leaders in Clinical Trial Services, Global Access Programs and have a Specialty Pharmaceutical portfolio with ten revitalized products.
“For the second half of the year gaining regulatory clearance for our dexrazoxane portfolio of drugs is a priority, along with the constant drive to convert the pipeline of new business and extend current customer relationships within CTS and GAP.
“In addition, we continue to explore opportunities to extend our global footprint and unlicensed supply market position.
“We anticipate another busy six months ahead.”
